Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
South Korea
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do Chungbuk National University Hospital, Cheonju, North Chungcheong Seoul National Univ. Hospital, Seoul, Seoul Asan Medical Center, Seoul, Seoul Gachon University Gil Medical Center, Incheon SAMSUNG Medical Center, Seoul